Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

被引：0
|
作者：
Chiara Garassino, Marina
Gadgeel, Shirish M.
Rodriguez-Abreu, Delvys
Felip, Enriqueta
Esteban, Emilio
Speranza, Giovanna
Hochmair, Maximilian
Francis Powell, Steven
Garon, Edward B.
Hui, Rina
Nogami, Naoyuki
Cristescu, Razvan
Morrissey, Michael
Loboda, Andrey
Kobie, Julie
Ayers, Mark
Piperdi, Bilal
Catherine Pietanza, Maria
Snyder, Alexandra
Reck, Martin
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[2] Karmanos Canc Inst, Detroit, MI USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Univ Las Palmas Gran Canaria, Complejo Hosp Univ Insular Maternoinfantil Gran C, Las Palmas Gran Canaria, Spain
[5] Hosp Univ Vall dHebron, Barcelona, Spain
[6] Hosp Univ Cent Asturias, Oviedo, Spain
[7] Univ Sherbrooke, Ctr Integre Cancerol Monteregie, Greenfield Pk, PQ, Canada
[8] Otto Wagner Hosp, Vienna, Austria
[9] Sanford Hlth, Sioux Falls, SD USA
[10] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[11] Westmead Hosp, Sydney, NSW, Australia
[12] Univ Sydney, Sydney, NSW, Australia
[13] Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[14] Merck & Co Inc, Kenilworth, NJ USA
[15] German Ctr Lung Res, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9521
引用
收藏
页数：2
相关论文
共 50 条
  • [1] KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.
    Gadgeel, Shirish M.
    Garassino, Marina Chiara
    Esteban, Emilio
    Speranza, Giovanna
    Felip, Enriqueta
    Hochmair, Maximilian J.
    Powell, Steven Francis
    Cheng, Susanna Y.
    Bischoff, Helge
    Peled, Nir
    Hui, Rina
    Reck, Martin
    Kurata, Takayasu
    Garon, Edward B.
    Boyer, Michael J.
    Yang, Jing
    Pietanza, Maria Catherine
    Rodriguez-Abreu, Delvys
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
    Garassino, M.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    Speranza, G.
    Reck, M.
    Hui, R.
    Boyer, M.
    Cristescu, R.
    Aurora-Garg, D.
    Albright, A.
    Loboda, A.
    Kobie, J.
    Lunceford, J.
    Ayers, M.
    Lubiniecki, G.
    Piperdi, B.
    Pietanza, M. C.
    Garon, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S216 - S217
  • [3] KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
    Gadgeel, S.
    Rodriguez-Abreu, D.
    Felip, E.
    Esteban, E.
    Speranza, G.
    Reck, M.
    Hui, R.
    Boyer, M.
    Garon, E. B.
    Horinouchi, H.
    Cristescu, R.
    Aurora-Garg, D.
    Lunceford, J.
    Kobie, J.
    Ayers, M.
    Piperdi, B.
    Pietanza, M. C.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 64 - 65
  • [4] KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo (pbo) plus pem and platinum for metastatic nonsquamous NSCLC
    Garassino, M. C.
    Gadgeel, S. M.
    Speranza, G.
    Felip, E.
    Gonzalez, E. Esteban
    Gomez, M. Domine
    Hochmair, M. J.
    Powell, S. F.
    Bischoff, H.
    Peled, N.
    Grossi, F.
    Jennens, R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Kurata, T.
    Gray, J. E.
    Schwarzenberger, P. O.
    Jensen, E.
    Abreu, D. Rodriguez
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S992 - S993
  • [5] Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 by STK11 and KEAP1 status
    Gadgeel, Shirish M.
    Rodriguez-Abreu, Delvys
    Felip, Enriqueta
    Esteban, Emilio
    Speranza, Giovanna
    Reck, Martin
    Hui, Rina
    Boyer, Michael
    Garon, Edward B.
    Horinouchi, Hidehito
    Cristescu, Razvan
    Aurora-Garg, Deepti
    Loboda, Andrey
    Lunceford, Jared
    Kobie, Julie
    Ayers, Mark
    Piperdi, Bilal
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2020, 80 (16)
  • [6] KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
    Gandhi, Leena
    Rodgriguez-Abreu, Delvys
    Gadgeel, Shirish
    Esteban, Emilio
    Felip, Enriqueta
    De Angelis, Flavia
    Domine, Manuel
    Clingan, Philip
    Hochmair, Maximilian J.
    Powell, Steven
    Cheng, Susanna Yee-Shan
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Boyer, Michael
    Rubio-Viqueira, Belen
    Novello, Silvia
    Kurata, Takayasu
    Gray, Jhanelle E.
    Vida, John J.
    Wei, Ziwen
    Yang, Jing
    Raftopoulos, Harry
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2018, 78 (13)
  • [7] KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
    Rodriguez Abreu, D.
    Garassino, M. C.
    Esteban, E.
    Speranza, G.
    Felip, E.
    Domine, M.
    Hochmair, M. J.
    Powell, S.
    Cheng, S. Y-S.
    Bischoff, H. G.
    Peled, N.
    Hui, R.
    Reck, M.
    Garon, E. B.
    Boyer, M.
    Grossi, F.
    Jennens, R.
    Yang, J.
    Pietanza, M. C.
    Gadgeel, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 164 - 164
  • [8] KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
    Rodriguez Abreu, D.
    Garassino, M. C.
    Esteban, E.
    Speranza, G.
    Felip, E.
    Domine, M.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y-S.
    Bischoff, H.
    Peled, N.
    Hui, R.
    Reck, M.
    Garon, E. B.
    Boyer, M.
    Grossi, F.
    Jennens, R.
    Yang, J.
    Pietanza, M. C.
    Gadgeel, S. M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Safety of pemetrexed (Pem) plus platinum (Plat) in combination with pembrolizumab (Pembro) for metastatic nonsquamous NSCLC: A post hoc analysis of KEYNOTE-189
    Garon, Edward B.
    Sun, Fangfang
    Muehlenbein, Catherine E.
    Kim, Jong S.
    Gadgeel, Shirish M.
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) plus pemetrexed (pem) plus platinum (plt) for metastatic NSCLC.
    Garassino, Marina Chiara
    Rodriguez-Abreu, Delvys
    Gadgeel, Shirish M.
    Gonzalez, Emilio Esteban
    Felip, Enriqueta
    De Angelis, Flavia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345